Hwankyu Kang

TL;DR: The optimized IPA compound Q203 inhibited the growth of MDR and XDR M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound.

TL;DR: It is found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv and the optimized IPAs 49 and 50 showed not only excellent oral bioavailability but also displayed significant colony-forming unit (CFU) reduction in mouse lung.

TL;DR: The first-in-human randomized, placebo-controlled, double-blind, dose-escalation Phase 1A trial (Q203-TB-PI-US001) was conducted to evaluate the safety, tolerability, and pharmacokinetics of telacebec as mentioned in this paper.

TL;DR: A new method of high-throughput screening (HTS) and high-contents screening ( HCS) based on the detection of morphological changes was designed, which induced senescence-like phenotypic changes in human melanoma A375 cells without serious cytotoxicity against normal cells.

TL;DR: The data indicate that therapy targeting both immune cells and cancer cells in the TME by Q702 can induce more effective clinical responses in patients with cancer, and Q702 may have great potential to broaden the coverage of populations benefiting from ICB-based immunotherapy.